Specifically, our results support previous findings and suggests that in addition to MMP-1, MMP-3 could be involved in NPC tumorigenesis, thus supporting the clinical utility of anti-MMP therapeutic agents for NPC. This evidence concerns the gene MMP3 and nasopharyngeal carcinoma.